Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.
Saved in:
| Title: | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. |
|---|---|
| Authors: | Ständer, Sonja1 (AUTHOR) Sonja.Staender@ukmuenster.de, Pinter, Andreas2 (AUTHOR) andreas.pinter@pinter-med.com, Hougeir, Firas G.3 (AUTHOR) hougeir@gmail.com, Guyot, Patricia4 (AUTHOR) Patricia.Guyot2@sanofi.com, Xu, Yingxin5 (AUTHOR) yingxin.xu@regeneron.com, Praestgaard, Amy H.6 (AUTHOR) Amy.Praestgaard@sanofi.com, Freemantle, Nick7 (AUTHOR) nicholas.freemantle@ucl.ac.uk, Rossi, Ana B.6 (AUTHOR) Gaelle.Le-Bagousse-Bego@sanofi.com, Bégo-Le-Bagousse, Gaëlle4 (AUTHOR), Wang, Zhixiao5 (AUTHOR) zhixiao.wang@regeneron.com, Noonan, Kerry6 (AUTHOR) Kerry.Noonan2@sanofi.com, Bastian, Mike8 (AUTHOR) mike.bastian@sanofi.com |
| Source: | Dermatology & Therapy. Sep2025, Vol. 15 Issue 9, p2537-2551. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938210 |
|---|---|
| DOI: | 10.1007/s13555-025-01479-y |
